MA54318A - Formulations de capsules - Google Patents

Formulations de capsules

Info

Publication number
MA54318A
MA54318A MA054318A MA54318A MA54318A MA 54318 A MA54318 A MA 54318A MA 054318 A MA054318 A MA 054318A MA 54318 A MA54318 A MA 54318A MA 54318 A MA54318 A MA 54318A
Authority
MA
Morocco
Prior art keywords
capsule formulations
capsule
formulations
Prior art date
Application number
MA054318A
Other languages
English (en)
Other versions
MA54318B1 (fr
Inventor
Manmohan Reddy Leleti
Jay P Powers
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70849818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA54318(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA54318A publication Critical patent/MA54318A/fr
Publication of MA54318B1 publication Critical patent/MA54318B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA54318A 2018-11-30 2019-11-27 Formulations de capsules MA54318B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773848P 2018-11-30 2018-11-30
PCT/US2019/063547 WO2020112961A1 (fr) 2018-11-30 2019-11-27 Formulations de capsules

Publications (2)

Publication Number Publication Date
MA54318A true MA54318A (fr) 2021-10-06
MA54318B1 MA54318B1 (fr) 2023-08-31

Family

ID=70849818

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54318A MA54318B1 (fr) 2018-11-30 2019-11-27 Formulations de capsules

Country Status (28)

Country Link
US (3) US20200170957A1 (fr)
EP (2) EP4233850A3 (fr)
JP (1) JP7342124B2 (fr)
KR (1) KR102586747B1 (fr)
CN (1) CN113164403A (fr)
AR (1) AR117219A1 (fr)
AU (1) AU2019389031B2 (fr)
BR (1) BR112021010285A2 (fr)
CA (1) CA3120999A1 (fr)
CL (1) CL2021001389A1 (fr)
CY (1) CY1126079T1 (fr)
DK (1) DK3886820T3 (fr)
ES (1) ES2943492T3 (fr)
FI (1) FI3886820T3 (fr)
HR (1) HRP20230551T1 (fr)
HU (1) HUE062551T2 (fr)
IL (1) IL283450B2 (fr)
LT (1) LT3886820T (fr)
MA (1) MA54318B1 (fr)
MD (1) MD3886820T2 (fr)
MX (1) MX2021006242A (fr)
PL (1) PL3886820T3 (fr)
PT (1) PT3886820T (fr)
RS (1) RS64250B1 (fr)
SG (1) SG11202105572UA (fr)
SI (1) SI3886820T1 (fr)
TW (1) TWI827745B (fr)
WO (1) WO2020112961A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2943492T3 (es) 2018-11-30 2023-06-13 Chemocentryx Inc Formulación de cápsulas
IL301209A (en) * 2020-10-28 2023-05-01 Chemocentryx Inc Treatment methods for hidradenitis suppurativa
WO2023225533A1 (fr) * 2022-05-19 2023-11-23 Dow Global Technologies Llc Utilisation de complexes interpolymères à base de peg pour une solubilisation améliorée de médicaments de classe ii bcs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038681A1 (es) 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
CN101065115A (zh) * 2004-11-24 2007-10-31 默克公司 取代酰胺的液体和半固体口服药物制剂
DE102005053066A1 (de) 2005-11-04 2007-05-10 Basf Ag Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
AU2009330194B2 (en) 2008-12-22 2015-07-09 Chemocentryx, Inc. C5aR antagonists
ES2613608T3 (es) * 2010-03-10 2017-05-24 Abbvie Ireland Unlimited Company Composiciones sólidas
RS56332B1 (sr) * 2010-06-24 2017-12-29 Chemocentryx Inc Antagonisti c5ar
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
KR20200015830A (ko) 2014-02-05 2020-02-12 레크 파마슈티칼스 디.디. 안드로겐 수용체 길항제의 고체 제약 조성물
BR112017006232B1 (pt) 2014-09-29 2022-10-11 Chemocentryx, Inc. Processos e intermediários na preparação de antagonistas de c5ar
MX2022006069A (es) 2016-01-14 2023-01-12 Chemocentryx Inc Metodo para tratar glomerulopatia c3.
CN109310686B (zh) 2016-04-04 2022-06-21 凯莫森特里克斯股份有限公司 可溶性C5aR拮抗剂
AU2018249310A1 (en) 2017-04-03 2019-10-17 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
US10376595B2 (en) * 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
CA3077395A1 (fr) 2017-10-30 2019-05-09 Chemocentryx, Inc. Composes deuteres utilises comme immunomodulateurs
US20190134020A1 (en) 2017-10-31 2019-05-09 Chemocentryx, Inc. C5aR INHIBITOR REDUCTION OF URINARY sCD163
WO2019236820A1 (fr) 2018-06-07 2019-12-12 Chemocentryx, Inc. Dosage et effet d'un antagoniste de c5a avec une vasculite associée aux anca
ES2943492T3 (es) 2018-11-30 2023-06-13 Chemocentryx Inc Formulación de cápsulas

Also Published As

Publication number Publication date
HRP20230551T1 (hr) 2023-08-18
MA54318B1 (fr) 2023-08-31
US20240299306A1 (en) 2024-09-12
AR117219A1 (es) 2021-07-21
BR112021010285A2 (pt) 2021-08-17
EP4233850A3 (fr) 2023-09-20
HUE062551T2 (hu) 2023-11-28
EP3886820A4 (fr) 2022-08-24
PL3886820T3 (pl) 2023-08-14
KR102586747B1 (ko) 2023-10-06
TWI827745B (zh) 2024-01-01
WO2020112961A1 (fr) 2020-06-04
RS64250B1 (sr) 2023-06-30
JP7342124B2 (ja) 2023-09-11
IL283450A (en) 2021-07-29
EP3886820B1 (fr) 2023-04-12
IL283450B1 (en) 2024-02-01
US11951214B2 (en) 2024-04-09
ES2943492T3 (es) 2023-06-13
EP3886820B8 (fr) 2023-05-17
JP2022510304A (ja) 2022-01-26
MD3886820T2 (ro) 2023-07-31
SI3886820T1 (sl) 2023-07-31
SG11202105572UA (en) 2021-06-29
MX2021006242A (es) 2021-09-10
TW202038952A (zh) 2020-11-01
AU2019389031A1 (en) 2021-06-17
IL283450B2 (en) 2024-06-01
US20220233453A1 (en) 2022-07-28
KR20210098489A (ko) 2021-08-10
PT3886820T (pt) 2023-05-24
FI3886820T3 (fi) 2023-05-25
CY1126079T1 (el) 2023-11-15
CN113164403A (zh) 2021-07-23
AU2019389031B2 (en) 2023-06-15
LT3886820T (lt) 2023-06-12
DK3886820T3 (da) 2023-05-15
US20200170957A1 (en) 2020-06-04
CA3120999A1 (fr) 2020-06-04
EP4233850A2 (fr) 2023-08-30
EP3886820A1 (fr) 2021-10-06
CL2021001389A1 (es) 2021-12-24

Similar Documents

Publication Publication Date Title
AU201714610S (en) Fragrance Capsule
MA50541A (fr) Formulations pharmaceutiques
ZA201903101B (en) Pharmaceutical formulations
MA42303A (fr) Formulations pharmaceutiques
IL262745A (en) Improved preparations containing drugs
ZA202006570B (en) Pharmaceutical formulations
IL283450A (en) capsule formulations
MA50068A (fr) Formulations de copanlisib
DK3280447T3 (da) Farmaceutiske formuleringer
GB201815267D0 (en) Capsule endoscopy
SG11202010792TA (en) Improved pharmaceutical formulations
DK3996688T3 (da) Farmaceutisk præparat
IL271908A (en) Over-compressed pharmaceutical preparations
IL273766A (en) Portion capsule
DK3728220T3 (da) Farmaceutiske forbindelser
ZAA201801557S (en) Capsule
ZAA201801556S (en) Capsule
CL2020000451S1 (es) Cápsula.
ZAF201800730S (en) Capsule
GB201806710D0 (en) Capsule
UA34979S (uk) Капсула
CL2017001143S1 (es) Cápsula
CL2017001144S1 (es) Cápsula
CL2017001140S1 (es) Cápsula
CL2017001146S1 (es) Cápsula